Role of Adiponectin in prostate cancer

Abstract

Obesity is defined as a chronic and excessive growth of adipose tissue. It has been associated with a high risk for development and progression of obesity-associated malignancies, while adipokines may mediate this association. Adiponectin is an adipose tissue-derived adipokines, with significant anti-diabetic, anti-inflammatory, anti-atherosclerotic and anti-proliferative properties. Plasma adiponectin levels are decreased in obese individuals, and this feature is closely correlated with development of several metabolic, immunological and neoplastic diseases. Recent studies have shown that prostate cancer patients have lower serum adiponectin levels and decreased expression of adiponectin receptors in tumor tissues, which suggests plasma adiponectin level is a risk factor for prostate cancer. Furthermore, exogenous adiponectin has exhibited therapeutic potential in animal models. In this review, we focus on the potential role of adiponectin and the underlying mechanism of adiponectin in the development and progression of prostate cancer. Exploring the signaling pathways linking adiponectin with tumorigenesis might provide a potential target for therapy.

Keywords: Obesity; Prostatic Neoplasms; Stress, Physiological.

Figure-1. Signaling pathways of adiponectin in prostate cancer cells.

JNK = c-Jun N-terminal kinase; STAT3 = signal transducer and activator of transcription; AMPK = AMP-activated protein kinase; TSC2 = tuberous sclerosis complex 2; mTOR = mammalian target of rapamycin; NF-KB = nuclear factor-KB; NOX = NADPH oxidase; OS = oxidative stress; ↓ indicates stimulation; indicates inhibition.